Search results
Results From The WOW.Com Content Network
Arena Pharmaceuticals Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. Arena focused on discovering drugs that act on G protein-coupled receptors (GPCRs). The company developed technology it called Constitutively Activated Receptor Technology (CART) that identified drug leads targeting ...
Arena Pharmaceuticals (NAS: ARNA) is revving up for the launch of its obesity drug, Belviq. The drug was the first obesity drug approved earlier this year but got held back by DEA scheduling while ...
In quick succession yesterday, trading in Arena Pharmaceuticals (NAS: ARNA) was halted, the Food and Drug Administration announced the approval of its obesity drug Belviq, the company followed ...
Arena Pharmaceuticals (NAS: ARNA) gained approval from the Food and Drug Administration for its obesity drug, Belviq, this summer, and now it's gearing up to market the drug with its partner Eisai.
Arena Pharmaceuticals (NAS: ARNA) posted its Q3 results, and while there was no ground-breaking news regarding its obesity drug, Belviq, the company did announce a new partnership with South ...
Obese patients have seen more choices for treatments over the past year, as new obesity drugs from VIVUS and Arena Pharmaceuticals have launched. A third drug, Orexigen's Contrave, looks as if it ...
For premium support please call: 800-290-4726 more ways to reach us more ways to reach us
In today's edition, health-care editor David Williamson checks up on Arena Pharmaceuticals. Arena has gone on quite a run over the past seven months, and its 400% year-to-date growth makes it one ...